Bruker (BRKR) Stock Forecast, Price Target & Predictions
BRKR Stock Forecast
Bruker stock forecast is as follows: an average price target of $73.75 (represents a 24.26% upside from BRKR’s last price of $59.35) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
BRKR Price Target
BRKR Analyst Ratings
Bruker Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Sep 23, 2024 | Patrick Donnelly | Citigroup | $80.00 | $67.54 | 18.45% | 34.79% |
Aug 27, 2024 | Brandon Couillard | Wells Fargo | $78.00 | $63.95 | 21.97% | 31.42% |
May 20, 2024 | Daniel Arias | Stifel Nicolaus | $77.00 | $76.47 | 0.69% | 29.74% |
May 05, 2021 | Tycho Peterson | J.P. Morgan | $60.00 | $68.86 | -12.87% | 1.10% |
Bruker Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 2 | 3 |
Avg Price Target | - | $79.00 | $78.33 |
Last Closing Price | $59.35 | $59.35 | $59.35 |
Upside/Downside | -100.00% | 33.11% | 31.98% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 15, 2024 | Barclays | - | Overweight | Initialise |
Sep 30, 2024 | Wolfe Research | - | Peer Perform | Downgrade |
Sep 23, 2024 | Citigroup | Buy | Buy | Hold |
Aug 28, 2024 | Wells Fargo | Overweight | Positive | Initialise |
Aug 27, 2024 | Wells Fargo | - | Overweight | Initialise |
Aug 07, 2024 | Cowen & Co. | Hold | Hold | Hold |
Jul 10, 2024 | Citigroup | Buy | Buy | Hold |
May 20, 2024 | Citigroup | Buy | Buy | Hold |
May 20, 2024 | Bank of America Securities | Buy | Buy | Hold |
Feb 15, 2024 | UBS | Buy | Buy | Hold |
Bruker Financial Forecast
Bruker Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $854.50M | $742.80M | $681.90M | $685.30M | $708.40M | $638.90M | $588.40M | $595.00M | $683.50M | $608.90M | $570.80M | $554.70M | $627.50M | $511.40M | $424.60M | $424.00M | $599.90M | $521.10M |
Avg Forecast | $1.16B | $1.01B | $934.80M | $884.80M | $1.07B | $928.90M | $876.46M | $843.59M | $1.01B | $866.46M | $799.47M | $729.88M | $807.45M | $714.61M | $647.82M | $639.76M | $680.10M | $609.98M | $588.22M | $572.58M | $661.93M | $575.19M | $537.10M | $513.06M | $603.36M | $484.92M | $391.49M | $443.92M | $576.91M | $494.16M |
High Forecast | $1.16B | $1.01B | $934.80M | $884.80M | $1.07B | $928.90M | $876.46M | $843.59M | $1.01B | $881.14M | $799.47M | $729.88M | $807.66M | $727.78M | $647.82M | $639.76M | $680.10M | $609.98M | $588.22M | $572.58M | $661.93M | $575.19M | $537.10M | $513.06M | $603.36M | $484.92M | $391.49M | $443.92M | $576.91M | $494.16M |
Low Forecast | $1.16B | $1.01B | $934.80M | $884.80M | $1.07B | $928.90M | $876.46M | $843.59M | $1.01B | $856.81M | $799.47M | $729.88M | $807.22M | $703.69M | $647.82M | $639.76M | $680.10M | $609.98M | $588.22M | $572.58M | $661.93M | $575.19M | $537.10M | $513.06M | $603.36M | $484.92M | $391.49M | $443.92M | $576.91M | $494.16M |
# Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 1.05% | 1.07% | 1.04% | 1.05% | 1.00% | 1.04% | 1.03% | 1.06% | 1.06% | 1.08% | 1.04% | 1.05% | 1.08% | 0.96% | 1.04% | 1.05% |
Bruker EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $144.90M | $160.50M | $117.50M | $153.10M | $161.40M | $155.30M | $108.00M | $125.70M | $143.90M | $137.20M | $114.60M | $115.80M | $147.40M | $104.80M | $56.80M | $36.00M | $136.90M | $99.60M |
Avg Forecast | $230.00M | $201.26M | $186.09M | $176.14M | $213.42M | $184.91M | $174.48M | $167.93M | $201.70M | $172.48M | $159.15M | $130.69M | $160.74M | $142.26M | $128.96M | $118.80M | $162.91M | $121.43M | $117.10M | $93.92M | $131.77M | $114.50M | $106.92M | $66.56M | $120.11M | $96.53M | $77.93M | $47.72M | $114.84M | $98.37M |
High Forecast | $230.00M | $201.26M | $186.09M | $176.14M | $213.42M | $184.91M | $174.48M | $167.93M | $201.70M | $175.41M | $159.15M | $156.82M | $160.78M | $144.88M | $128.96M | $142.57M | $195.49M | $121.43M | $117.10M | $112.70M | $131.77M | $114.50M | $106.92M | $79.88M | $120.11M | $96.53M | $77.93M | $57.27M | $114.84M | $98.37M |
Low Forecast | $230.00M | $201.26M | $186.09M | $176.14M | $213.42M | $184.91M | $174.48M | $167.93M | $201.70M | $170.56M | $159.15M | $104.55M | $160.69M | $140.08M | $128.96M | $95.04M | $130.33M | $121.43M | $117.10M | $75.13M | $131.77M | $114.50M | $106.92M | $53.25M | $120.11M | $96.53M | $77.93M | $38.18M | $114.84M | $98.37M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 1.13% | 0.91% | 1.29% | 0.99% | 1.28% | 0.92% | 1.34% | 1.09% | 1.20% | 1.07% | 1.74% | 1.23% | 1.09% | 0.73% | 0.75% | 1.19% | 1.01% |
Bruker Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $205.50M | $88.10M | $57.10M | $76.50M | $97.40M | $88.10M | $49.50M | $61.60M | $76.00M | $87.10M | $57.60M | $56.70M | $68.90M | $54.30M | $24.10M | $10.50M | $68.60M | $61.30M |
Avg Forecast | $177.60M | $148.00M | $118.40M | $100.64M | $154.74M | $110.12M | $93.55M | $84.18M | $138.51M | $88.97M | $75.97M | $71.43M | $101.12M | $93.69M | $72.05M | $64.94M | $83.27M | $81.82M | $66.84M | $51.33M | $86.59M | $65.49M | $56.29M | $35.44M | $83.14M | $46.54M | $8.50M | $14.61M | $87.28M | $55.96M |
High Forecast | $177.60M | $148.00M | $118.40M | $100.64M | $154.74M | $110.12M | $93.55M | $84.18M | $138.51M | $96.27M | $75.99M | $85.72M | $105.79M | $96.67M | $72.05M | $77.92M | $99.92M | $81.82M | $66.84M | $61.60M | $86.59M | $65.49M | $56.29M | $42.52M | $83.14M | $46.54M | $8.50M | $17.53M | $87.28M | $55.96M |
Low Forecast | $177.60M | $148.00M | $118.40M | $100.64M | $154.74M | $110.12M | $93.55M | $84.18M | $138.51M | $84.60M | $75.95M | $57.14M | $96.45M | $92.20M | $72.05M | $51.95M | $66.62M | $81.82M | $66.84M | $41.07M | $86.59M | $65.49M | $56.29M | $28.35M | $83.14M | $46.54M | $8.50M | $11.69M | $87.28M | $55.96M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.03% | 0.94% | 0.79% | 1.18% | 1.17% | 1.08% | 0.74% | 1.20% | 0.88% | 1.33% | 1.02% | 1.60% | 0.83% | 1.17% | 2.83% | 0.72% | 0.79% | 1.10% |
Bruker SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $205.20M | $177.60M | $177.90M | $162.70M | $164.70M | $144.80M | $152.20M | $145.70M | $156.50M | $141.40M | $134.70M | $131.90M | $132.90M | $114.90M | $104.30M | $125.60M | $133.10M | $125.90M |
Avg Forecast | $276.20M | $241.68M | $223.47M | $211.52M | $256.29M | $222.06M | $209.52M | $201.66M | $242.21M | $207.13M | $191.12M | $169.42M | $193.02M | $170.83M | $154.86M | $154.01M | $168.63M | $145.82M | $140.62M | $121.75M | $158.24M | $137.50M | $128.40M | $82.44M | $144.24M | $115.92M | $93.59M | $176.00M | $137.91M | $118.13M |
High Forecast | $276.20M | $241.68M | $223.47M | $211.52M | $256.29M | $222.06M | $209.52M | $201.66M | $242.21M | $210.64M | $191.12M | $203.30M | $193.07M | $173.98M | $154.86M | $184.82M | $202.36M | $145.82M | $140.62M | $146.10M | $158.24M | $137.50M | $128.40M | $98.92M | $144.24M | $115.92M | $93.59M | $211.20M | $137.91M | $118.13M |
Low Forecast | $276.20M | $241.68M | $223.47M | $211.52M | $256.29M | $222.06M | $209.52M | $201.66M | $242.21M | $204.82M | $191.12M | $135.53M | $192.97M | $168.22M | $154.86M | $123.21M | $134.90M | $145.82M | $140.62M | $97.40M | $158.24M | $137.50M | $128.40M | $65.95M | $144.24M | $115.92M | $93.59M | $140.80M | $137.91M | $118.13M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 1.15% | 1.06% | 0.98% | 0.99% | 1.08% | 1.20% | 0.99% | 1.03% | 1.05% | 1.60% | 0.92% | 0.99% | 1.11% | 0.71% | 0.97% | 1.07% |
Bruker EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | $1.41 | $0.60 | $0.39 | $0.52 | $0.66 | $0.60 | $0.33 | $0.41 | $0.50 | $0.58 | $0.38 | $0.37 | $0.45 | $0.35 | $0.16 | $0.07 | $0.45 | $0.40 |
Avg Forecast | $1.20 | $1.00 | $0.80 | $0.68 | $1.05 | $0.74 | $0.63 | $0.57 | $0.94 | $0.60 | $0.51 | $0.47 | $0.68 | $0.63 | $0.49 | $0.55 | $0.72 | $0.55 | $0.45 | $0.42 | $0.59 | $0.44 | $0.38 | $0.33 | $0.56 | $0.31 | $0.06 | $0.23 | $0.59 | $0.38 |
High Forecast | $1.20 | $1.00 | $0.80 | $0.68 | $1.05 | $0.74 | $0.63 | $0.57 | $0.94 | $0.65 | $0.51 | $0.47 | $0.71 | $0.65 | $0.49 | $0.55 | $0.72 | $0.55 | $0.45 | $0.42 | $0.59 | $0.44 | $0.38 | $0.33 | $0.56 | $0.31 | $0.06 | $0.23 | $0.59 | $0.38 |
Low Forecast | $1.20 | $1.00 | $0.80 | $0.68 | $1.05 | $0.74 | $0.63 | $0.57 | $0.94 | $0.57 | $0.51 | $0.47 | $0.65 | $0.62 | $0.49 | $0.55 | $0.72 | $0.55 | $0.45 | $0.42 | $0.59 | $0.44 | $0.38 | $0.33 | $0.56 | $0.31 | $0.06 | $0.23 | $0.59 | $0.38 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.06% | 0.95% | 0.80% | 0.95% | 0.91% | 1.09% | 0.73% | 0.98% | 0.85% | 1.31% | 1.00% | 1.13% | 0.80% | 1.11% | 2.78% | 0.31% | 0.76% | 1.06% |
Bruker Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
FNA | Paragon 28 | $6.06 | $11.50 | 89.77% | Buy |
OFIX | Orthofix Medical | $17.33 | $31.00 | 78.88% | - |
LUNG | Pulmonx | $7.12 | $11.93 | 67.56% | Buy |
IRTC | iRhythm | $81.44 | $121.17 | 48.78% | Buy |
LIVN | LivaNova | $49.01 | $70.50 | 43.85% | Buy |
KIDS | OrthoPediatrics | $28.74 | $39.60 | 37.79% | Buy |
CNMD | CONMED | $70.47 | $96.00 | 36.23% | Buy |
BIO | Bio-Rad Laboratories | $368.92 | $482.50 | 30.79% | Buy |
BRKR | Bruker | $59.35 | $73.75 | 24.26% | Buy |
ZBH | Zimmer Biomet | $108.41 | $133.57 | 23.21% | Hold |
AORT | Artivion | $27.46 | $30.60 | 11.43% | Buy |
ITGR | Integer | $126.53 | $138.00 | 9.07% | Buy |
SRDX | Surmodics | $37.57 | $39.50 | 5.14% | Buy |
GKOS | Glaukos | $131.38 | $119.33 | -9.17% | Buy |
BRKR Forecast FAQ
Is Bruker a good buy?
Yes, according to 7 Wall Street analysts, Bruker (BRKR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of BRKR's total ratings.
What is BRKR's price target?
Bruker (BRKR) average price target is $73.75 with a range of $60 to $80, implying a 24.26% from its last price of $59.35. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bruker stock go up soon?
According to Wall Street analysts' prediction for BRKR stock, the company can go up by 24.26% (from the last price of $59.35 to the average price target of $73.75), up by 34.79% based on the highest stock price target, and up by 1.10% based on the lowest stock price target.
Can Bruker stock reach $90?
BRKR's average twelve months analyst stock price target of $73.75 does not support the claim that Bruker can reach $90 in the near future.
What are Bruker's analysts' financial forecasts?
Bruker's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.72B (high $3.72B, low $3.72B), average EBITDA is $740.74M (high $740.74M, low $740.74M), average net income is $442.58M (high $442.58M, low $442.58M), average SG&A $889.54M (high $889.54M, low $889.54M), and average EPS is $2.99 (high $2.99, low $2.99). BRKR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.99B (high $3.99B, low $3.99B), average EBITDA is $793.49M (high $793.49M, low $793.49M), average net income is $544.64M (high $544.64M, low $544.64M), average SG&A $952.87M (high $952.87M, low $952.87M), and average EPS is $3.68 (high $3.68, low $3.68).
Did the BRKR's actual financial results beat the analysts' financial forecasts?
Based on Bruker's last annual report (Dec 2023), the company's revenue was $2.96B, beating the average analysts forecast of $2.81B by 5.51%. Apple's EBITDA was $557.8M, beating the average prediction of $550.76M by 1.28%. The company's net income was $427.2M, beating the average estimation of $331.8M by 28.75%. Apple's SG&A was $706.9M, beating the average forecast of $672.73M by 5.08%. Lastly, the company's EPS was $2.9, beating the average prediction of $2.35 by 23.29%. In terms of the last quarterly report (Dec 2023), Bruker's revenue was $854.5M, beating the average analysts' forecast of $807.45M by 5.83%. The company's EBITDA was $144.9M, missing the average prediction of $160.74M by -9.85%. Bruker's net income was $205.5M, beating the average estimation of $101.12M by 103.22%. The company's SG&A was $205.2M, beating the average forecast of $193.02M by 6.31%. Lastly, the company's EPS was $1.41, beating the average prediction of $0.683 by 106.37%